· Form D filing · Baseline
Reported sold as filed: $7,500,000 · Offering amount as filed: $7,500,000
SEC source checked 29 Oct 2026. This is the issuer’s historical filing, not a current valuation.
View original evidence ↗On its website, the company describes its work as “About Tempest Therapeutics Developing differentiated solutions for the next generation of in vivo CAR-T therapies Tempest Therapeutics is a clinical-stage biotechnology company focused on pioneering…”.
These sources establish that the firm lists the company. The observation date records when RiseFinder captured the relationship; it does not establish when the investment happened.
No tracked VC backing is recorded.
· Form D filing · Baseline
Reported sold as filed: $7,500,000 · Offering amount as filed: $7,500,000
SEC source checked 29 Oct 2026. This is the issuer’s historical filing, not a current valuation.
View original evidence ↗